RxDoctor Payments Data

Azadeh Fotouhie, MD

Gastroenterology · Albuquerque, NMNPI 1407269467

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 37.8% of the total. 2025 is the largest year on record at $654, more than ten times the $43 reported in 2021.

$1,779in general payments, 2019–2025

Across 96 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$673
  • Johnson & Johnson$163
  • Boston Scientific$162
  • Takeda Pharmaceuticals U.S.A., Inc.$143
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$122
  • Bristol Myers Squibb$114
  • plus $402 from 13 others

What the payments were for

  • Food & beverage$1,779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,779 in reported general payments places this provider in the 55th percentile of 81 gastroenterology providers in New Mexico.

See all gastroenterology providers in New Mexico

Medicare billing

Part B allowed, 2024
$126,846
Medicare patients
316
Services billed
5,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase48$181,301
Humira(Cf) PenAdalimumab13$88,194
Mesalamine17$11,369
Omeprazole250$3,622
CholestyramineCholestyramine (With Sugar)15$1,251
Budesonide DrBudesonide16$1,093
Colestipol Hcl15$989
Famotidine21$584
Desipramine Hcl17$504
Pantoprazole Sodium19$317
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$249
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl16$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$673$181,30148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 81 gastroenterology providers in New Mexico.

Other gastroenterology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →